Strongest evidence
- Increased 25-hydroxyvitamin D levels (16 studies, high strength): 14 of 16 studies found beneficial effects, with doses from 240–4000 IU/day (or weekly boluses up to 50,000 IU). Effects appeared within 8–12 weeks.
- Improved quality of life (7 studies, moderate strength): all 7 studies reported benefits, with doses around 4000 IU/day or 60,000 IU/week in clinical populations (e.g., Alzheimer’s, fibromyalgia, cancer).
- Reduced inflammation (5 studies, moderate strength): all 5 studies showed small effects, with a meta-analysis reporting a moderate reduction (SMD −0.40). Most evidence comes from older adults and those with rheumatoid arthritis.
- Improved insulin sensitivity (9 studies, moderate strength): 6 of 9 studies found benefits, particularly in vitamin D-deficient individuals with PCOS, gestational diabetes, or obesity. Doses of 1000–4000 IU/day were common.
- Reduced CRP (8 studies, moderate strength) and IL-6 (8 studies, moderate strength): around 5 of 8 studies for each outcome showed moderate effects, primarily in clinical populations with underlying inflammation.
Mixed or weaker evidence
- Depression symptoms (4 studies, moderate strength): 3 of 4 studies found small beneficial effects, but the evidence base is small and one neutral review had methodological limitations.
- Reduced PTH (4 studies, moderate strength): 3 of 4 studies showed small-to-moderate effects, but one study in bariatric surgery patients found no benefit.
- Triglycerides (7 studies, moderate strength): only 4 of 7 studies showed small benefits, and effects were context-dependent (stronger in metabolic conditions).
- HOMA-IR and TNF-α (5 studies each, moderate strength): both showed about 3 of 5 studies with small benefits, but neutral results in several populations and inconsistent dosing limit confidence.
Effective dose patterns
Across outcomes, daily doses of 1000–5000 IU were most common, with some studies using weekly boluses (e.g., 50,000 IU or 60,000 IU). The consistent range for insulin sensitivity, CRP, IL-6, and quality of life is 1000–4000 IU/day. Higher doses (5000–8000 IU/day) appeared in studies on improving vitamin D levels, but no single optimal dose applies across all outcomes.
Population insights
Benefits were most consistent in vitamin D-deficient individuals and clinical populations (e.g., PCOS, diabetes, obesity, inflammatory conditions, older adults). In replete or healthy individuals, effects were often modest or absent. For example, insulin sensitivity benefits were strongest in those with low baseline vitamin D, and CRP/IL-6 reductions were mainly seen in groups with existing inflammation.
Notable caveats
- Publication bias is a recurring concern across multiple syntheses — null results may be underrepresented in the literature.
- Many studies combined vitamin D with other supplements (magnesium, whey protein), making it difficult to isolate its independent effect.
- Effect sizes were often small to moderate, and several outcomes had a high proportion of neutral results (e.g., 3 of 8 studies for CRP and IL-6 were neutral).
- Dose and form were not always reported, limiting dose-response conclusions. Vitamin D3 (cholecalciferol) was used where specified.
- Most evidence comes from short-to-medium duration trials (median 8–16 weeks), so long-term effects are less clear.